These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8882342)

  • 1. CD26 and HIV infection.
    Callebaut C; Hovanessian AG
    Res Virol; 1996; 147(1):67-9. PubMed ID: 8882342
    [No Abstract]   [Full Text] [Related]  

  • 2. HIV envelope glycoprotein-induced cell killing by apoptosis is enhanced with increased expression of CD26 in CD4+ T cells.
    Jacotot E; Callebaut C; Blanco J; Rivière Y; Krust B; Hovanessian AG
    Virology; 1996 Sep; 223(2):318-30. PubMed ID: 8806567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 envelope gp120 and viral particles block adenosine deaminase binding to human CD26.
    Valenzuela A; Blanco J; Callebaut C; Jacotot E; Lluis C; Hovanessian AG; Franco R
    Adv Exp Med Biol; 1997; 421():185-92. PubMed ID: 9330696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential risks of eliciting antibodies enhancing HIV-1 infection of monocytic cells by vaccination with V3 loops of unmatched HIV-1 isolates.
    Jiang S; Neurath AR
    AIDS; 1992 Mar; 6(3):331-2. PubMed ID: 1567580
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunogenicity of the GPGRAFY epitope on synthetic peptides.
    Chen YH; Yu T; Bai Y; Dierich MP
    Immunol Lett; 1999 Sep; 69(3):353-4. PubMed ID: 10528800
    [No Abstract]   [Full Text] [Related]  

  • 6. HIV-1 neutralization directed to epitopes other than linear V3 determinants.
    Steimer KS; Klasse PJ; McKeating JA
    AIDS; 1991; 5 Suppl 2():S135-43. PubMed ID: 1726953
    [No Abstract]   [Full Text] [Related]  

  • 7. The significance of hypersialylation of dipeptidyl peptidase IV (CD26) in the inhibition of its activity by Tat and other cationic peptides. CD26: a subverted adhesion molecule for HIV peptide binding.
    Smith RE; Talhouk JW; Brown EE; Edgar SE
    AIDS Res Hum Retroviruses; 1998 Jul; 14(10):851-68. PubMed ID: 9671214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Theoretical conformational NMR analysis of peptide RP342 of the immunogenic fragment of HIV-1 protein gp120].
    Andrianov AM; Akhrem AA
    Dokl Akad Nauk; 1996 Nov; 351(3):401-3. PubMed ID: 9011297
    [No Abstract]   [Full Text] [Related]  

  • 9. [Conformational analysis of major antigenic determinant of HIV-1 gp120 protein using the NMR spectroscopy data].
    Andrianov AM
    Mol Biol (Mosk); 1996; 30(5):1173-83. PubMed ID: 8992304
    [No Abstract]   [Full Text] [Related]  

  • 10. Reactivity of Argentine serum samples against synthetic V3-based HIV-1 peptides.
    Pampuro SE; Calarota SA; Marquina SA; Rabinovich RD; Libonatti OV
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(5):527-8. PubMed ID: 8757435
    [No Abstract]   [Full Text] [Related]  

  • 11. Epitope vaccine: a new strategy against HIV-1.
    Chen YH; Xiao Y; Yu T; Dierich MP
    Immunol Today; 1999 Dec; 20(12):588-9. PubMed ID: 10562711
    [No Abstract]   [Full Text] [Related]  

  • 12. Discontinuous epitopes on gp120 important in HIV-1 neutralization.
    Ho DD; Fung MS; Yoshiyama H; Cao Y; Robinson JE
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1337-9. PubMed ID: 1281654
    [No Abstract]   [Full Text] [Related]  

  • 13. The epidemiological evolution of HIV-1 subtypes B and E among heterosexuals and injecting drug users in Thailand, 1992-1997.
    Limpakarnjanarat K; Ungchusak K; Mastro TD; Young NL; Likhityingvara C; Sangwonloy O; Weniger BG; Pau CP; Dondero TJ
    AIDS; 1998 Jun; 12(9):1108-9. PubMed ID: 9662211
    [No Abstract]   [Full Text] [Related]  

  • 14. Type-specific and cross-reactive neutralizing antisera against HIV elicited by V3-peptide heptalysine octomers.
    Looney DJ; Li M; Walfield A; Hosein B; Badel P; Wang CY; Wong-Staal F
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1381. PubMed ID: 1466961
    [No Abstract]   [Full Text] [Related]  

  • 15. HIV-1 diversity in heterosexual population in Slovakia, Ukraine and the Czech Republic.
    Mayer V; Apetrei C; Habekova M; Tchentsova N; Bruckova M; Klaskala W; Baum MK; Brun-Vézinet F; Simon F
    AIDS; 1998 Jun; 12(9):1106-8. PubMed ID: 9662210
    [No Abstract]   [Full Text] [Related]  

  • 16. Progress with HIV vaccines.
    Biberfeld G; Emini EA
    AIDS; 1991; 5 Suppl 2():S129-33. PubMed ID: 1845044
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect on serologic reactivity of P-to-W substitution in the apex of the V3 loop of the HIV-1 subtype B glycoprotein.
    Vanden Haesevelde M; DeLeys RJ; Van Geel A; Vanderborght B; de Sá M; Van Eynde G; Saman E
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jan; 17(1):91-2. PubMed ID: 9436765
    [No Abstract]   [Full Text] [Related]  

  • 18. HIV and CD26.
    Dalgleish A
    Nat Med; 1995 Sep; 1(9):881-2. PubMed ID: 7585208
    [No Abstract]   [Full Text] [Related]  

  • 19. Epitopes of HIV-1 glycoproteins recognized by the human immune system.
    Laal S; Zolla-Pazner S
    Chem Immunol; 1993; 56():91-111. PubMed ID: 7680869
    [No Abstract]   [Full Text] [Related]  

  • 20. Polyvalent, recombinant HIV-1 virus-like particles: novel HIV-1 vaccine strategies.
    Wagner R; Deml L; Wolf H
    Antibiot Chemother (1971); 1994; 46():48-61. PubMed ID: 7826039
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.